<DOC>
	<DOCNO>NCT02125682</DOCNO>
	<brief_summary>Atorvastatin statin significantly decrease LDL level . At 10 mg/day , atorvastatin increase HDL level 4-5 % . At 80 mg/day , atorvastatin increase HDL level . However , atorvastatin protective 80 mg/day 10 mg/day . This due good reduction LDL level 80 mg , also think 80 mg/day atorvastatin superior 10 mg/day improve QUALITY HDL , improve HDL particle number function ( good anti-oxydant activity )</brief_summary>
	<brief_title>The HDL Particle Protection Study</brief_title>
	<detailed_description>The dyslipidemia Type II diabetes characterized anomaly metabolism biological activity atherogenic lipoprotein contain apoB100 ( VLDL , IDL LDL ) antiatherogenic HDL contain apoAI and/or apoAII . Such metabolic functional anomaly closely associate elevated oxidative stress , endothelial dysfunction premature macrovascular atherosclerotic disease . The ratio atherogenic cholesterol ( VLDL , IDL , LDL cholesterol ) relative HDL cholesterol ( HDL-C ) normolipidemic subject typically less 3 ; contrast , ratios 4 typical dyslipidemia Type II diabetes indicative disequilibrium proatherogenic versus antiatherogenic plasma lipoprotein level , frequently due low HDL-C concentration ( &lt; 40 mg/dl ) . Such condition favor enhanced deposition cholesterol arterial wall progression atherosclerotic disease . Atorvastatin potent synthetic HMG-CoA reductase inhibitor markedly lower plasma level LDL cholesterol ( LDL-C ) ; addition , atorvastatin lower plasma level triglyceride ( TG ) TG-rich lipoproteins equally raises level HDL-C apoAI , major HDL apolipoprotein . Atorvastatin-induced decrease plasma TG intimately relate decreased VLDL level , accelerate VLDL turnover normalize intravascular remodel apoB-containing lipoprotein . Importantly , atorvastatin reduces activity plasma cholesteryl ester transfer protein ( CETP ) hepatic lipase ( HL ) , thereby lead normalize remodel LDL HDL particle population . Furthermore , recent study reveal atherogenic Type IIB hyperlipidemia , atorvastatin induces dose-dependent progressive increase capacity plasma HDL mediate cellular cholesterol efflux via SRB1 receptor pathway . Plasma HDL highly heterogeneous . When isolated basis density ultracentrifugation , human HDL separate two major subfractions , large , light HDL2 small , dense HDL3 . HDL remodel CETP , HL LCAT alter absolute relative concentration HDL2 HDL3 plasma . It remain contradictory however whether plasma level HDL2 HDL3 predictor cardiovascular risk . HDL exert spectrum antiatherosclerotic action ; central among reverse cholesterol transport , capacity HDL protect LDL oxidative stress , anti-inflammatory action HDL arterial wall cell well antithrombotic activity . We recently find small , dense HDL3 particle exert potent protection atherogenic LDL subspecies oxidative stress normolipidemic subject HDL-associated paraoxonase ( PON ) 1 , platelet-activating factor acetylhydrolase ( PAF-AH ) lecithin : cholesterol acyltransferase ( LCAT ) activity contribute antioxidative property . HDL particles however dysfunctional diabetic dyslipidemias ; example , diabetic HDL deficient antioxidant activity , addition , cholesterol-efflux capacity impair . Such dysfunction may lead impairment antiatherogenic action HDL diabetic dyslipidemia . Working hypothesis : The investigator hypothesize atorvastatin increase plasma level HDL subfractions potent antioxidant activity result enhance surface core remodel TG-rich lipoprotein , ( VLDL-1 VLDL-2 ) , reduce CETP activity , stimulation apoAI production . Indeed , Asztalos et al . show atorvastatin induced significant increase α1 , α2 , pre- α1 pre-β1 HDL subfractions dyslipidemic subject mean LDL-C , 198 mg/dl ; mean TG , 167 mg/dl .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patient 3 criterion : 1 . Patient diabetes mellitus , define least 1 follow : Fasting glucose &gt; 125 mg/dL confirm 2 occasion HbA1C &gt; 6.5 % Patients receive glucose lower agent ( oral subcutaneous ) 2 . Lipid profile ALL follow characteristic : Triglycerides &gt; 150 mg/dL HDL &lt; 45 mg/dL LDL &lt; 190 mg/dL 3 . Lp ( ) level &lt; 30 mg/dL 1 . Patients know coronary artery disease define least one following : Prior myocardial infarction Prior PCI Prior CABG Known coronary stenosis &gt; 50 % coronary angiography A non invasive study reveal myocardial ischemia ( stress test , nuclear perfusion study stress echo ) 2 . Poor diabetic control define HbA1c &gt; 8.5 % precede 3 month 3 . Patients know diabetic retinopathy , nephropathy neuropathy 4 . Patients creatinin clearance &lt; 75 ml/min calculate CockcroftGault equation 5 . Patients receive lipid lower therapy within 6 week prior inclusion ( statin , fibrates , ezetimibe , niacin , resin binding agent ) 6 . Patients underlying malignancy infection inflammatory disease 7 . Patients SGPT SGOT CK &gt; 2.5 time upper reference value 8 . Patients allergic statin experience prior significant side effect statins elevation liver enzymes CK &gt; 2.5 upper reference value 9 . Patients older 80 10 . Females premenopausal 11 . Patients unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HDL</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Inflammation</keyword>
</DOC>